Truncated RAF kinases drive resistance to MET inhibition in MET-addicted cancer cells. by Petti, C et al.
Oncotarget221www.impactjournals.com/oncotarget
www.impactjournals.com/oncotarget/ Oncotarget, Vol. 6, No. 1
Truncated RAF kinases drive resistance to MET inhibition in 
MET-addicted cancer cells
Consalvo Petti1, Gabriele Picco1,2, Maria Luisa Martelli1, Elena Trisolini2,3, Enrico 
Bucci4, Timothy Perera5, Claudio Isella1,2 and Enzo Medico1,2
1 Candiolo Cancer Institute - FPO IRCCS, Italy
2 Department of Oncology, University of Torino, Italy
3 Istituto Nazionale Biostrutture e Biosistemi, Roma, Italy
4 Biodigitalvalley Srl, Pont Saint Martin, Aosta, Italy
5 Janssen Research and Development, Oncology Discovery, Beerse, Belgium
Correspondence to: Enzo Medico, email: enzo.medico@ircc.it
Keywords: drug resistance; RAF1; BRAF; MET; gastric cancer
Received: October 12, 2014 Accepted: November 14, 2014 Published: November 15, 2014
This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, 
distribution, and reproduction in any medium, provided the original author and source are credited. 
ABSTRACT
Constitutively active receptor tyrosine kinases (RTKs) are known oncogenic 
drivers and provide valuable therapeutic targets in many cancer types. However, 
clinical efficacy of RTK inhibitors is limited by intrinsic and acquired resistance. To 
identify genes conferring resistance to inhibition of the MET RTK, we conducted 
a forward genetics screen in the GTL-16 gastric cancer cell line, carrying MET 
amplification and exquisitely sensitive to MET inhibition. Cells were transduced 
with three different retroviral cDNA expression libraries and selected for growth in 
the presence of the MET inhibitor PHA-665752. Selected cells displayed robust and 
reproducible enrichment of library-derived cDNAs encoding truncated forms of RAF1 
and BRAF proteins, whose silencing reversed the resistant phenotype. Transduction 
of naïve GTL-16 cells with truncated, but not full length, RAF1 and BRAF conferred 
in vitro and in vivo resistance to MET inhibitors, which could be reversed by MEK 
inhibition. Induction of resistance by truncated RAFs was confirmed in other MET-
addicted cell lines, and further extended to EGFR-addicted cells. These data show 
that truncated RAF1 and BRAF proteins, recently described as products of genomic 
rearrangements in gastric cancer and other malignancies, have the ability to render 
neoplastic cells resistant to RTK-targeted therapy. 
INTRODUCTION
Deregulated RTKs have been implicated in the 
development and progression of numerous human cancers 
[1]. Aberrant RTK activation can be caused by different 
mechanisms, such as autocrine/paracrine stimulation, 
chromosomal translocations, amplification/overexpression 
and gain-of-function mutations. In addicted cancers, 
abnormal RTK activity is required for tumor growth 
and survival [2]. Hence, in such cases, pharmacological 
targeting of activated RTKs can profoundly affect 
growth and survival of tumor cells, leading to clinically 
meaningful responses in patients [3, 4].
Recently, the Hepatocyte Growth Factor (HGF) 
receptor MET emerged as a promising RTK therapeutic 
target in a variety of human cancers [5-7]. Drugs 
targeting the HGF/MET axis, either small-molecule 
kinase inhibitors or monoclonal antibodies (mAbs), are 
currently under clinical testing [8-10]. Copy number 
gains of the MET gene are particularly frequent in human 
gastric carcinoma, where protein overexpression occurs 
in about one quarter of the cases [11]. Gastric cancer 
cells carrying MET amplification and overexpression 
have been found to be particularly susceptible to its 
pharmacological inhibition [12], which corroborates the 
therapeutic potential of MET inhibition in MET-addicted 
gastric cancers. However, RTK-targeted therapies are 
not effective in all cases, and even responsive patients 
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invariably develop secondary resistance, either for 
compensations in the signalling networks or for activation/
overexpression of a different RTK or other cell signalling 
proteins [13-15]. It is increasingly clear that a better 
understanding of the resistance mechanisms, along with 
the identification of novel response modifiers, is crucial to 
increase the effectiveness of targeted therapy. 
We therefore set to identify potential mediators of 
resistance to MET inhibition in cancer cells. There are 
two main screening strategies to generate drug-resistant 
cells starting from a sensitive population: (i) induction of 
spontaneous resistance by long-term drug treatment [16]; 
(ii) functional screens by transduction of the sensitive 
cells with cDNA or shRNA libraries [17]. Determinants 
of resistance to MET inhibition have been successfully 
identified by long-term drug treatments [18, 19], which 
however rely on genetic events that could either be pre-
existing in a small fraction of cells or occur during the 
selection process by de novo mutagenesis. In both cases 
the spectrum of identifiable events is limited. We thus 
performed a complementary screening based on the gain-
of-function approach, by which target cells are transduced 
with full length cDNA expression libraries and then 
subjected to a selective treatment invariably inducing cell 
death or growth arrest. Only cells expressing exogenous 
cDNAs conferring resistance to the treatment will grow 
and form resistant populations [17, 20]. The model of 
choice was the GTL-16 cell line, derived from a poorly 
differentiated gastric adenocarcinoma, in which the 
MET gene locus is amplified, leading to overexpression 
of constitutively active MET protein [18]. GTL-16 cells 
are addicted to MET and respond to small-molecule 
MET inhibitors with proliferative block and apoptosis 
[21]. For the screen, GTL-16 cells were transduced with 
multiple retroviral cDNA expression libraries and selected 
with the MET inhibitor PHA-665752 (PHA) [21]. The 
“Xenorarray” approach was then employed to identify, by 
gene expression arrays, library-derived cDNAs enriched 
in the selected, resistant populations [22, 23] (Figure 1A). 
RESULTS
Transduction of GTL-16 cells with expression 
libraries and selection of PHA-resistant cells
GTL-16 cells were transduced in duplicate with 
retroviral cDNA expression libraries obtained from 
Mouse Testis (MmT), Human Spleen (HsS) and Human 
Kidney (HsK), or with GFP as a control. Microarray-
based quantification of library-derived transcripts 
(see Supplementary Methods) [22] confirmed that all 
transduced populations carried a consistent number of 
detectable library-derived transcripts, in addition to a 
small fraction of background transcripts, also detected in 
GFP-transduced cells (Supplementary Figure 1). GFP- or 
library-transduced GTL-16 cells were selected in presence 
of the MET inhibitor PHA at 300nM for eight weeks. By 
this time no spontaneous resistance was previously found 
to occur in non-transduced cells. Cells recovered after 
selection were assayed for their ability to grow in the 
presence or absence of PHA. All populations of library-
transduced selected GTL-16 cells displayed a significant 
resistance to PHA compared to unselected counterparts 
and to both selected and unselected GFP-transduced cells 
(Figure 1B). These results suggest a biological effect of 
the library not explained with insertional mutagenesis, 
but likely deriving from the expression of exogenous 
transcripts.
Identification and validation of library-derived 
cDNAs encoding for RAF1 variants in cells that 
survived selection with MET inhibitor PHA
To identify cDNAs promoting resistance to PHA, 
we quantified the abundance of library-derived transcripts 
in transduced cells before and after PHA selection. In 
this way, we avoided the need of isolating clones and 
performing multiple screening cycles. In the case of the 
mouse testis library, endogenous and exogenous transcripts 
are from different species, and sequence divergence 
between orthologue transcripts can be exploited as a 
“molecular barcode” for species-specific hybridization 
on microarrays [22]. In the case of human kidney and 
spleen libraries, we verified that the retroviral vector-
specific primer used for reverse transcription (T7-pFB) 
allows selective reverse transcription of library-derived 
transcripts (Supplementary Figure 1). In all infections, 
numerous array probes displayed a higher signal in 
selected cells compared to unselected, indicating that cells 
expressing the respective transcripts were enriched by the 
selection. Many other transcripts were lost, indicating 
that cells carrying them had died during the selection. 
To identify the genes that were reproducibly enriched in 
selected cells, we calculated, for each transcript, the ratio 
of the array signal before and after selection. Interestingly, 
the RAF1 transcript showed a strong enrichment in all 
infections/selections (Table 1 and Figure 1C, D and E).
We validated RAF1 enrichment in all selections by 
realtime quantitative PCR (RT-PCR) (see Supplementary 
Methods). Four pairs of PCR primers were designed, 
two against murine Raf1 (for the MmT-transduced cells) 
and two against human RAF1 (for the HsK and HsS-
transduced cells), covering the 5’ portion and the 3’ 
portion of the transcripts (Figure 2A). Surprisingly, only 
the primer pairs corresponding to the 3’ region confirmed 
murine RAF1 mRNA enrichment in all selections 
(Figure 2B and C). Subsequently, Western blot analysis 
of the enriched populations compared to controls were 
performed. In the selected, resistant GTL-16 populations, 
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RAF1 antibody detected lower molecular weight bands, 
compared to the full length control, confirming the 
hypothesis that the enriched cDNAs encoded for truncated 
proteins, lacking the N-terminal region (Figure 2D and E). 
To verify the composition of the expression 
libraries before and after PHA selection, we conceived 
an approach based on deep-sequencing of retroviral 
library inserts, exploiting targeted reverse transcription 
(see Supplementary Methods) of RNA obtained from 
GTL-16 transduced with HsS library, before and after 
selection, in two independent replicates, using the GS 
FLX 454 to maximize reads length. The single lanes 
yielded respectively 420456 and 365867 reads for the two 
unselected populations and 119949 and 144378 reads for 
the selected populations. Average read length was around 
300 nt. All the reads were mapped with BLAST on RAF1 
mRNA sequence to evaluate its abundance and sequence. 
RAF1 coverage was quite low in unselected cells, and 
evenly distributed across all the transcript sequence 
(Supplementary Figure 2A). As expected, RAF1 coverage 
was much higher in selected cells, with a sharp decline 
of coverage 5’ from nucleotides 1000-1500 of the RAF1 
mRNA in both selected samples (Supplementary Figure 
2B). To identify reads compatible with RAF1 truncations, 
we selected all the reads with matches on both RAF1 and 
retroviral vector sequence. This analysis revealed that in 
both selections some reads captured the point of transition 
from the RAF1 sequence to the vector cloning site, all 
at the same site of RAF1 (Supplementary Figure 2C). 
This result shows that, albeit in the original expression 
library the major form of RAF1 cDNA is full length, PHA 
selection drives enrichment of a variant that contains 
the kinase domain, but lacks the N-terminal regulatory 
domain. No other truncation forms were identified by the 
analysis, suggesting that this is the most represented form 
of RAF1 in two independent selections.
To search for truncated forms of RAF1 in published 
data, we interrogated the ProteinQuest (BioDigitalValley) 
data mining platform that integrates information from 
scientific literature, data repositories and biological 
images. This tool generated an image derived from the 
sum of all published pictures of SDS-page/Western 
Blots against the C-terminal portion of RAF1 and 
highlighted the presence of multiple possible truncated 
forms of this protein (Supplementary Figure 3 and 
Supplementary Methods). We then cloned and sequenced 
RAF1 containing transcripts from all the selected cell 
populations. In all cases the RAF1 transcripts enriched 
Figure 1: Generation of PHA-resistant GTL-16 cells by transduction with expression libraries. (A) Schema of the screening 
design. GTL-16 cells are transduced with cDNA expression libraries and selected in the presence of PHA-665752 (PHA). Abundance of 
library-derived transcripts is quantified before and after selection, to identify enriched cDNAs potentially rendering GTL-16 cells resistant 
to MET inhibition. (B) GLT-16 cells transduced with Mouse Testis (MmT1 and 2), Human Kidney (HsK1 and 2) and Human Spleen (HsS1 
and 2) libraries or GFP control vector were treated (SELECTED) or not (UNSELECTED) with 300nM PHA for 8 weeks, after which cells 
were assayed with 200nM PHA for 2 weeks and subsequently fixed, stained, and photographed. (C,D,E) microarray analysis of library-
derived transcripts on GTL-16 cells transduced with (C) mouse testis, (D) human kidney and (E) human spleen libraries. Each MA plot 
displays average Log2 signal in unselected+selected cells (x-axis), vs. Log2ratio between selected and unselected cells (y-axis) for library-
derived mRNAs. Values in MA plots are averaged from two independent transduction-selection experiments.
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in selected cells were truncated, at M350 in the MmT, at 
P308 in the HsK and, as expected, at G248 in the HsS 
resistant GTL-16 cells (Supplementary Figure 4A).
Resistance to MET inhibitors of GTL-16 cells 
expressing truncated Raf1 is reversed by Raf1 
silencing
To test whether Raf1 silencing could revert PHA 
resistance in selected GTL-16 cells, we performed a loss-
of-function assay. This could be possible only for MmT-
Table 1: Enrichments of library-derived cDNAs in GTL-16 cells transduced and selected for 
growth in the presence of MET inhibitor. Bold values indicate enrichment > 4-fold in at least one 
of the two screenings. 
Illumina PROBE_ID Gene Symbol Fold EnrichmentScreening 1
Fold Enrichment
Screening 2
Mouse Testis Library
scl28523.18.1_12-S Raf1 550.5 215.7
scl056407.1_179-S Trpc4ap 435.0 1.0
scl18457.19.17_30-S Trpc4ap 319.7 1.0
scl52811.6_3-S A930001C03Rik 20.0 1.0
scl0113846.1_329-S V1ra4 11.4 0.8
scl32698.6.1_30-S Irf3 0.8 312.3
scl000245.1_108-S Irf3 0.9 245.0
scl00024.1_6-S Irf3 1.0 124.9
Human Kidney Library
ILMN_1813489 RAF1 6.7 157.6
ILMN_3251662 HINT3 4.4 10.2
ILMN_1669663 BCR 24.2 1.4
ILMN_3310196 MIR1302-5 22.4 1.5
ILMN_1744426 LOC644629 21.9 0.8
ILMN_1666966 INS 18.1 1.0
ILMN_1664124 FLJ13224 14.0 1.4
ILMN_1726466 HDHD3 13.1 0.5
ILMN_2321634 RAD17 0.9 414.2
ILMN_1687782 RAD17 0.7 354.2
ILMN_1771084 ACSM3 0.6 91.8
ILMN_1685952 ACSM3 1.1 44.7
ILMN_1760858 RAB8A 0.7 12.8
Human Spleen Library
ILMN_1813489 RAF1 420.8 350.3
ILMN_1794364 CTSW 11.4 8.8
ILMN_1735594 CDC42SE2 11.1 9.0
ILMN_2173919 MYO9A 10.9 9.5
ILMN_1797031 HSPBAP1 10.0 3.8
ILMN_1665212 EDC4 9.1 4.6
ILMN_1777190 CFD 6.6 23.1
ILMN_1844692 FOXO3 7.6 13.9
ILMN_1761058 ACAD11 6.3 9.2
ILMN_1751396 BAG5 6.6 8.9
ILMN_1745329 PRR14 5.8 8.8
ILMN_1784766 MCM3AP 6.1 7.0
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transduced cells, because in these cells the library-derived 
Raf1 is murine and therefore can be silenced by murine 
specific shRNAs without interference with endogenous 
human RAF1. Two different murine Raf1 shRNAs and 
the non-silencing control lentiviral supernatants were used 
to transduce MmT-selected, resistant GTL-16 population, 
and Western Blot analysis showed a good silencing only 
with shRNA targeting the C-terminal portion of the gene 
(Figure 3A). RT-PCR analysis confirmed the capability of 
Raf1 shRNA-3’ to downregulate the expression of Raf1 
in MmT-selected GTL-16 (Figure 3B). A growth assay 
confirmed that resistance of MmT-selected GTL-16 cells 
to PHA was lost when murine Raf1 was silenced (Figure 
3C). These results prove that RAF1 plays a causative role 
in mediating resistance to MET inhibition.
BRAF is an additional mediator of PHA-665752 
resistance in GTL-16 cells.
The data obtained in previous experiments prompted 
to perform a new screening with this rationale: (i) 
Darwinian selection of the most resistant cells, carrying 
truncated Raf1, may have not allowed enrichment of other 
possible interesting, though weaker, hits; (ii) murine Raf1 
shRNA-3’ was found to silence very efficiently the murine 
Raf1 in infected-selected GTL-16 and to be specific 
for the murine transcript and therefore not to interfere 
with endogenous human RAF1 in GTL-16 cells; (iii) 
therefore, use of GTL-16 transduced with murine Raf1 
shRNA-3’ as recipient cells for the MmT library should 
allow additional weaker candidates to emerge upon PHA 
selection. Accordingly, wild-type GTL-16 cells were first 
transduced with murine Raf1 shRNA-3’ and then with the 
mouse testis library or GFP, in duplicate. After 8 weeks 
of in PHA selection under the same conditions described 
above, only library-infected, selected cells became 
resistant to PHA (Figure 4A), although to a lower extent 
that the previously selected cells. In both independent 
selections, xenoarray analysis showed that the murine 
cDNA enriched in selected cells was Braf (Figure 4B). 
We performed PCR validation using two oligonucleotide 
pairs, one corresponding to the 5’ and the other to the 
3’ portion of the Braf transcript and, again, only the 
C-terminal primer pair confirmed cDNA enrichment 
in both selections (Figure 4C). Western Blot analysis 
demonstrated that also the Braf protein is truncated in 
selected cells (Figure 4D). We then cloned and sequenced 
the enriched Braf transcript, and found a truncated 
transcript starting at M475 (Supplementary Figure 4B). 
Figure 2: Validation of RAF1 cDNA enrichment. (A) Schematic diagram of RAF1 protein domain structure (648 aa) with 
approximative position of the 5’ and 3’ RT-PCR products. (B, C) Realtime PCR validation of RAF1 transcript enrichment in (B) the GTL-
16 Mouse Testis (MmT1 and 2), (C) Human Kidney (HsK1 and 2) and Human Spleen (HsS1 and 2) screenings. The y-axis represents the 
40-Ct values, previously scaled against the PGK1 housekeeper gene. (D, E) Western Blot analysis of RAF1 protein expression in (D) the 
MmT unselected (UNS) and selected (SEL) cells or in (E) the HsK and HsS unselected (UNS) and selected (SEL) cells, as indicated; GFP 
transduced cells were used as negative control (CTRL). The less abundant band of ~80kD in the “HsK2 SEL” lane is compatible with an 
upstream in frame alternative translation start site in the vector sequence. The RAF1 protein was detected by an antibody against the RAF1 
C-terminus portion of both human and murine origin. GTL-16 cells transduced with human RAF1 full-length as control for the full size 
protein detection; vinculin was used as loading control.
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Therefore, also in this case only the C-terminal portion, 
containing the kinase catalytic domain of Braf is expressed 
in resistant cells, while the N-terminal portion, containing 
regulatory domains, is missing.
Truncated but not full length RAF kinases confer 
resistance to MET inhibition, which is reversed by 
MEK1/2 inhibition
To confirm whether RAF1 and BRAF were drivers 
of resistance to MET inhibition, we transduced full length 
human RAF1 and BRAF in wild-type GTL-16 cells. 
RT-PCR and Western Blot analysis confirmed robust 
expression of both RAF1 and BRAF transcripts and 
proteins (Supplementary Figure 5A and B). However, a 
growth assay performed on transduced and control cells 
did not show resistance to PHA nor to JNJ38877605 
(JNJ, a novel “second generation” MET inhibitor) [24] 
in a range of concentrations (Supplementary Figure 5C 
and D). It appeared therefore likely that both RAF1 and 
BRAF confer resistance to MET inhibition only when 
lacking the N-terminal regulatory portion. We therefore 
transduced GTL-16 cells with truncated human RAF1 
and BRAF, resembling those actually observed in 
human tumors (Supplementary Figure 4). RT-PCR and 
Western Blot analyses (Supplementary Figure 6A and 
B) confirmed robust expression of truncated transcripts 
and proteins. We found that cells expressing truncated 
RAFs were resistant to the MET inhibitors JNJ (Figure 
5A) and PHA (Supplementary Figure 7). We reasoned that 
RAF blocking drugs would be able to restore sensitivity 
to PHA in GTL-16 cells expressing truncated RAFs. 
However, RAF1 selective inhibitors are not available, and 
Figure 3: Silencing of truncated murine Raf1 restores sensitivity to PHA. (A) Western Blot analysis on resistant Mouse 
Testis (MmT) GTL-16 cells, transduced with non silencing scramble vector (scr) or two different murine-specific shRNAs against Raf1: 
shRNA-5’, targeting the 5’ portion of the Raf1 transcript, and shRNA-3’, targeting the 3’ portion. The protein was detected by an antibody 
against the C-terminus of Raf1 (bands with lower molecular weight respect to the ~60kD truncated RAF1 band are non-specific and 
appear also in non-transduced cells); vinculin was used as loading control. (B) Realtime PCR validation of murine Raf1 mRNA specific 
silencing by the shRNA-3’ construct. The y-axis represents the percentage of inhibition in scramble and shRNA-3’ compared to resistant 
MmT GTL-16 cells (SEL); Pgk1 housekeeper gene was used as control. (C) Resistant GTL-16 MmT cells, either untransduced (MmT 
SEL) or transduced with non-silencing shRNA (scramble) or shRNA-5’ or shRNA-3’ silencing constructs were treated with increasing 
concentrations of PHA (as indicated) for 1 weeks and subsequently fixed, stained, and photographed.
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truncated forms of BRAF have been previously associated 
with resistance to the corresponding inhibitors [25]. We 
therefore decided to target MEK, a downstream effector of 
RAF proteins. GTL-16 cells expressing truncated RAF1 or 
BRAF were therefore tested for sensitivity to the MEK1/2 
inhibitor AZD6244, either alone or in combination with 
PHA. While ineffective alone, AZD6244 reverted RAF-
driven resistance to MET inhibition in GTL-16 cells 
(Supplementary Figure 8)
To evaluate whether resistance to MET inhibition 
in GTL-16 cells transduced with truncated BRAF 
or RAF1 was also maintained in vivo, we performed 
xenograft experiments in nude mice. Since PHA has poor 
pharmacokinetic properties and low oral bioavailability 
[21], we treated the grafted nude mice with the orally 
available JNJ (40mg/kg/day). JNJ administration 
exhibited a prominent cytostatic effect on tumors obtained 
from GTL-16 control cells, whose growth was halted. 
Conversely, xenografts from cells transduced with either 
of the two truncated RAFs continued growing despite 
treatment with the MET inhibitor (Figure 5B). These 
results show that expression of truncated RAF kinases 
renders GTL-16 cells resistant to MET inhibition also in 
vivo.
Truncated RAFs confer resistance to RTK 
inhibition in different tumor types
To investigate whether truncated RAF1 and BRAF 
could drive resistance to RTK inhibition also in other 
cell lines and tissues, Hs746T (gastric carcinoma, MET 
addicted), NCI-H1993 (non-small cell lung cancer, 
MET addicted), EBC1 (lung squamous cell carcinoma, 
Figure 4: PHA-resistant cells emerging after murine Raf1 silencing are enriched for truncated Braf. (A) Growth assay 
on murine Raf1-shRNA-3’-GTL-16 cells transduced with GFP or mouse testis library. Library-transduced, selected populations (MmT1 
SEL and MmT2 SEL) are resistant to 200nM PHA treatment for 2 weeks. (B) MA plot of the xenoarray analysis displaying enrichment of 
mouse testis library-derived cDNAs after selection (y-axis) vs average Log2 signal (x-axis). Values are averaged from two independent 
transduction-selection experiments. (C) Realtime PCR validation of enriched murine Braf transcript in GFP and Mouse Testis (MmT1 
and 2) selections. The y-axis represents the 40-Ct values, previously scaled against the Pgk1 housekeeper gene. Black and white columns 
represent, respectively, the 3’ and 5’ RT-PCR products. Only the 3’ RT-PCR confirmed cDNA overexpression in both selections. (D) 
Western Blot analysis on murine Raf1-shRNA-3’-GTL-16 cells transduced with GFP or mouse testis library (MmT1 and MmT2). Braf 
was detected by an antibody against the C-terminus portion; vinculin was used as loading control. The full-length (FL), endogenous human 
crossreacting BRAF, is faintly detectable in all samples.
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MET addicted) and NCI-H508 (caecal adenocarcinoma, 
EGFR addicted), were transduced with truncated RAFs 
and GFP control vector. RT-PCR and Western Blot 
analysis confirmed truncated RAFs expression at high 
levels (Supplementary Figure 6A and B). As shown in 
Figure 5A, all MET-addicted cells acquired resistance 
to MET inhibition by JNJ when transduced with either 
of the truncated RAFs. Identical results were obtained 
when PHA was used to inhibit MET, or when the EGFR 
targeted drug Cetuximab was used on NCI-H508 cells 
(Supplementary Figure 7). These data show that resistance 
to RTK inhibition can be induced by truncated RAF1 or 
BRAF in multiple cell lines, of different origin (stomach, 
lung and intestine) and addicted to different RTKs (MET, 
EGFR). 
Figure 5: Expression of truncated RAF1 or BRAF confers resistance to MET inhibition in vitro and in vivo. (A) Cell-
viability assay at different concentrations of JNJ on GTL-16, Hs746T, NCI-H1993 and EBC1 cells (as indicated) transduced with truncated 
RAFs or control vector. (B) Tumor growth curves of xenografts from GTL-16 cells transduced with the control vector (left panel) or 
truncated RAFs (right panel) in nude mice treated with JNJ (40 mg/kg/day) or vehicle.
Oncotarget229www.impactjournals.com/oncotarget
DISCUSSION 
The HGF-MET axis, tightly regulated under normal 
conditions and involved in epithelial cell proliferation and 
motility during development, appears to play an important 
role in oncogenesis, particularly in the development of the 
invasive and metastatic phenotypes [5]. MET inhibition is 
an attractive opportunity for molecularly targeted cancer 
therapy [6, 7]. However, intrinsic or acquired resistance 
can lead to limited therapeutic effectiveness and disease 
progression. Similar to other RTKs, development of 
resistance to MET inhibitors may occur via MET 
amplification [26] or sequence mutations preventing drug 
binding [27]. It has also been previously reported that 
the activation of EGFR family receptors [28], or KRAS, 
BRAF or AKT [29] can bypass MET inhibition. Indeed, 
several drugs have been developed to inhibit MET protein, 
but the mechanisms of resistance have not been fully 
elucidated [5]. 
To anticipate potential resistance mechanisms, we 
carried out an in vitro functional screening to identify 
genes conferring MET inhibitor resistance to GTL-16, a 
MET-addicted gastric carcinoma cell line with high level 
amplification of the MET gene locus. Here, we report the 
identification of truncated RAF1 and BRAF as strong 
determinants of resistance to MET inhibition in GTL-
16 cells. The experimental approach described above is 
extremely reproducible. We identified truncated forms 
of RAF genes in three different cDNA libraries of two 
different species, and results were confirmed in in vitro 
and in vivo models.
It must be acknowledged that the truncated variants 
of RAF genes found by our screens are likely to derive 
from cDNA cloning artifacts. It is possible that the source 
of truncated transcripts could be attributed to secondary 
mRNA structures in the phase of reverse transcription 
prior to cloning cDNAs in the retroviral expression 
library. However, truncated and fusion RAF1 and BRAF 
transcripts have been found to occur in several cancer 
cell lines and tumor samples [30-35]. Recently, long-term 
treatment of GTL-16 cells with a MET inhibitor was found 
to generate spontaneously resistant cells. A fusion gene 
coding for a truncated BRAF protein was identified in the 
resistant population, although not functionally validated 
as the driver of the resistance [19]. In our work, we find 
that RAF1 could play a significant role in resistance to 
RTK-targeted treatment. To our knowledge, such a causal 
relationship has not been reported before. 
The functional and biochemical properties of RAF 
truncated variants have been extensively studied since 
the discovery in 1983 of a viral oncogene encoding 
a RAF1 kinase lacking the N-terminal domain [36]. 
Indeed, lack of the N-terminal RAF regulatory domains 
is known to render RAF kinases constitutively active 
[37]. In the past, several studies supported the ability of 
truncated RAF1 to induce transformation in fibroblasts 
[38-40], but only recently many aberrant forms of RAF 
genes have been described and associated to cancer 
progression. The presence of BRAF and RAF1 fusions 
has been reported to activate mitogen activated kinase-like 
protein (MAPK) in pilocytic astrocytoma [34]. Another 
study found rearrangements in gastric, prostate cancer 
and melanoma that involve again fusions containing 
BRAF or RAF1 segments [41]. All these rearrangements 
were characterized by 5’ regulatory elements of highly 
expressed genes fused to the C-terminal portion of 
BRAF or RAF1 gene. As an example, in prostate cancer 
rearrangements occurred between untranslated exon 1 of 
SLC45A3 (a prostate-specific androgen responsive gene) 
and exon 8 of BRAF (GenBank GU149303) or between 
exon 13 of ESRP1 (an epithelial splicing regulatory 
protein) and exon 6 of RAF1 (GenBank GU149302). All 
these alterations involve the loss of N-terminal regulatory 
domain of RAFs, indicating that the aberrant proteins are 
constitutively active. Intriguingly, in GTL-16 cells selected 
with the MET inhibitor we have found a murine truncated 
Braf sequence that is homologous and share exactly the 
same predicted open reading frame of a rearranged BRAF 
found in human prostate cancer. 
In addition to genomic rearrangements in cancer, 
RAF proteins may be physiologically truncated by 
proteolytic cleavage as part of cell survival pathways. In 
particular, cleavage of RAF1 by caspase-9 was found to 
protect hematopoietic cells from IL-3 withdrawal-induced 
apoptosis [42]. Also in this case the resulting truncated 
RAF1 lacks the N-terminal domain, so that the C-terminal 
kinase domain can directly interact with the mitochondria 
to inhibit apoptosis. A similar mechanism could enable 
cancer cells to escape apoptosis induced by RTK-targeted 
drugs. 
The identification of translocations affecting RAF 
genes in prostate, gastric cancers and melanoma provided 
evidence for the key role of RAF signaling in a subset 
of these cancers and suggested possible new personalized 
cancer therapy. Several studies identified activated RAF 
proteins as possible candidates for drug treatment [43], 
but also highlighted possible mechanisms of resistance 
to RAF inhibition [37, 44, 45], including truncations [25, 
46]. In principle tumors with activated RAFs but resistant 
to their inhibition should be sensitive to inhibitors of 
downstream hubs in the same pathway, such as MEK 
inhibitors. Indeed, in our model, the MEK inhibitor 
AZD6244 abrogated RAF-driven resistance of GTL-16 
cells to MET inhibition. This study therefore indicates 
a role of RAF truncations in resistance to RTK-targeted 
therapy, and provides a rationale for future testing of 
combinatorial treatment approaches. 
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MATERIALS AND METHODS
Cell Culture, Reagents, viral transduction and 
drug selection
GTL-16 cells, not commercially available, were 
a kind gift from Silvia Giordano, University of Torino; 
EBC1 cells were obtained from the JCRB cell bank; 
Hs746T, NCI-H1993 and NCI-H508 cell lines were 
obtained from American Type Culture Collection (ATCC). 
Commercial cells were used within 6 months from their 
arrival. All cells were regularly authenticated by the 
Promega Cell ID system, which is based on sequencing 
known STRs (short-tandem repeats). GTL-16, EBC1 
and Hs746T cells were cultured in Dulbecco’s modified 
Eagle’s medium (DMEM) (Gibco). NCI-H1993 and 
NCI-H508 cell lines were cultured in RPMI-1640 medium 
(Gibco). The medium was supplemented with 10% FBS 
(Sigma) in a humidified atmosphere of 5% CO2. Human 
full length RAF1 cDNA was purchased from RZPD 
German Resource Center for Genome Research and cloned 
into the pMSCV retroviral vector (Stratagene). Full-length 
human BRAF cDNA in retroviral pBabe vector (Addgene) 
was a gift by Federica Di Nicolantonio. Retroviral 
supernatants were produced in Phoenix Amphotropic 
packaging cells. The pMSCV-empty retroviral and 
supernatant was used as control. Human truncated RAF1 
and BRAF cDNAs were custom-synthesized by Geneart 
and cloned into the pRRLsin-PPThCMV-wpre lentiviral 
vector [47]. All vectors above described were sequenced 
to confirm truncated RAFs cloning. To downregulate 
the murine Raf1 transcript, two lentiviral short hairpin 
RNAs (shRNA) of the Mission shRNA Target Set 
(Sigma) were used, named shRNA-5’ for N-Terminus 
portion (TRCN0000055139), shRNA-3’ for C-Terminus 
portion (TRCN0000055141) and pLKO.1-puro (cat. 
num. SHC001) non silencing control vector. All lentiviral 
supernatants were produced by Lipofectamine transfection 
of HEK293T cells. Transduction procedures, described 
in detail in Supplementary Methods, were followed by 
selection with puromycin (2 ng/ml) for retroviral vectors 
and hygromycin (400ug/ml) for lentiviral vectors. MET 
small-molecule inhibitors for in-vitro assays, PHA-
665752 and JNJ38877605, were obtained, respectively, 
from Sequoia Research Products and Johnson&Johnson; 
JNJ38877605 for in-vivo experiments from Timothy 
Perera; the EGFR inhibitor Cetuximab from the hospital 
pharmacy at our Institution; MEK inhibitor AZD6244 
from Sequoia Research Products.
Growth and cell-viability assays
For growth assays, 104 cells of each cell line 
were seeded in duplicate in 24-well plates. Cells were 
treated with different drug concentrations. The stain 
was performed with crystal violet after cell fixing with 
a solution of 3% paraformaldeide and 1% glucose. Cell 
viability was measured after 3, 7 and 14 days. Cell 
viability was determined seeding 1,5 x 103 cells in 100 
µl of final volume for each well, in a 96-well plate. Cells 
were cultured in the specific medium with 10% FBS 
(Sigma). The next day cells were treated at increasing 
drug concentrations. After 96 hours, ATP measurement 
was performed with Cell TITER-Glo Luminescent Cell 
Viability Assay (Promega) and the luminescence were 
measured with Perkin Elmer Victor 2 (GMI). Each test 
was conducted in triplicate.
Sequencing of truncated RAFs
To identify RAF1 and BRAF truncation 
points in GTL-16 selected cell lines, we generated 
PCR products using pFB vector sense primer 
5’-GGCTGCCGACCCCGGGGGTGG-3’ and 
antisense specific primers for C-terminal of target 
transcripts (murine and human RAF1 (NM_029780.3 
and NM_002880.3 respectively) and murine Braf 
(NM_139294.5) respectively) and we cloned them into 
the pCR TOPO vector using the TOPO-TA Cloning Kit 
(Invitrogen). Sequencing was performed with TOPO TA 
M13 sense primer 5´-GTAAAACGACGGCCAG-3´ and 
antisense primer 5’-CAGGAAACAGCTATGAC-3’. All 
sequencing experiments were performed by automated 
sequencing by ABI Prism 3730 (Applied Biosystems). 
Western blotting
For Western blot the following antibodies were 
used: polyclonal antibody against human RAF1 (Upstate 
- Cat.# 07-396), polyclonal antibody against human and 
murine phosphorilated BRAF (Ser445) (Cell Signaling 
Technology - Cat.# 2696); monoclonal antibody against 
murine Raf1 (Santa Cruz Biotechnology - Cat.# sc-7267); 
and antibody against vinculin (Sigma - Cat.# V9131). Total 
cellular proteins were extracted by solubilizing the cells in 
boiling Laemmli buffer followed by sonication. Extracts 
were centrifuged at 12,000 rpm for 30 min and normalized 
with the BCA Protein Assay Reagent Kit (Pierce); 30 μg 
of lysates were run on 10% SDS-polyacrylamide gels, 
transferred onto nitrocellulose membranes (Hybond; GE 
Healthcare) and incubated with the antibodies overnight at 
4°C. Nitrocellulose-bound antibodies were detected by the 
enhanced chemiluminescence (ECL) system (Promega).
Xenograft experiments
All animal procedures were approved by the Ethical 
Committee of the Candiolo Cancer Institute and the Italian 
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Ministry of Health. GTL-16 wild-type, GTL-16 human-
delta-RAF1 and GTL-16 human-delta-BRAF cells (2 × 
106) were resuspended in 200ul of PBS and inoculated 
subcutaneously into the right posterior flanks of 6-week-
old female CD-1 nu/nu mice (Charles River Laboratories). 
Mice were treated orally with 40 mg/kg/day of JNJ (the 
maximum tolerated dose) or vehicle. Treatment was 
initiated when the tumor volume reached approximately 
50 mm3. Tumor volume was monitored every 3 days for 
21 days.
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